Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Rapid onset of efficacy of rasagiline in early Parkinson's disease.

Zambito Marsala S, Vitaliani R, Volpe D, Capozzoli F, Baroni L, Belgrado E, Borsato C, Gioulis M, Marchini C, Antonini A.

Neurol Sci. 2013 Nov;34(11):2007-13. doi: 10.1007/s10072-013-1437-2. Epub 2013 May 1.

PMID:
23636872
2.

Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

Tolosa E, Stern MB.

Eur J Neurol. 2012 Feb;19(2):258-64. doi: 10.1111/j.1468-1331.2011.03484.x. Epub 2011 Aug 5.

PMID:
21819487
3.

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Hoy SM, Keating GM.

Drugs. 2012 Mar 26;72(5):643-69. doi: 10.2165/11207560-000000000-00000. Review. Erratum in: Drugs. 2012 Apr 16;72(6):870-1.

PMID:
22439669
4.

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group.

Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30.

PMID:
11575866
5.

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Jost WH, Klasser M, Reichmann H.

Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2. German.

PMID:
18833504
6.
8.

Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.

Stocchi F, Rabey JM.

Eur J Neurol. 2011 Dec;18(12):1373-8. doi: 10.1111/j.1468-1331.2011.03512.x. Epub 2011 Sep 6.

PMID:
21895884
9.
10.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
11.

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.

Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW.

Mov Disord. 2004 Aug;19(8):916-23.

PMID:
15300656
12.

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I; Parkinson Study Group TEMPO; PRESTO Investigators.

J Neurol Sci. 2006 Oct 25;248(1-2):78-83. Epub 2006 Jul 7.

PMID:
16828804
13.

Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.

Marconi S, Zwingers T.

Eur Rev Med Pharmacol Sci. 2014 Jul;18(13):1879-82. Review.

14.

[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].

Levin OS, Boĭko AN, Ivanov AK.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 2):42-7. Russian.

PMID:
21389939
15.

Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.

Zhang L, Zhang Z, Chen Y, Qin X, Zhou H, Zhang C, Sun H, Tang R, Zheng J, Yi L, Deng L, Li J.

Int J Neuropsychopharmacol. 2013 Aug;16(7):1529-37. doi: 10.1017/S1461145713000175. Epub 2013 Apr 3.

PMID:
23551956
16.

Rasagiline: a guide to its use in Parkinson's disease.

Keating GM, Lyseng-Williamson KA, Hoy SM.

CNS Drugs. 2012 Sep 1;26(9):781-5. doi: 10.2165/11207570-000000000-00000.

PMID:
22834567
17.

Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM; LEGATO Investigators.

Neurologist. 2011 Nov;17(6):318-24. doi: 10.1097/NRL.0b013e31822f6872.

PMID:
22045282
18.

Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.

Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J.

Pharmacol Res. 2013 Aug;74:78-86. doi: 10.1016/j.phrs.2013.05.005. Epub 2013 Jun 2. Review.

PMID:
23735235
19.

Rasagiline: a review of its use in the management of Parkinson's disease.

Oldfield V, Keating GM, Perry CM.

Drugs. 2007;67(12):1725-47. Review.

PMID:
17683172
20.

Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.

Frakey LL, Friedman JH.

J Neuropsychiatry Clin Neurosci. 2017 Winter;29(1):22-25. doi: 10.1176/appi.neuropsych.15050118. Epub 2016 Nov 10.

PMID:
27829318

Supplemental Content

Support Center